Oslo, Norway, 22 June, 2020 – Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that Magnus Jäderberg, Chief Medical Officer of Targovax, will present an overview of the company at the upcoming Virtual European Biotech Investor Day 2020 hosted by Solebury Trout, Goodwin, Deutsche Bank and Nasdaq.
Participants will be able to submit questions electronically during the presentation, with answers provided at the discretion of the company on an individual basis afterwards.
Details are as follows:
Date/Time: Thursday June 25, at 5:30 pm CET / 11:30 am EDT
To access the presentation, please login here.
Archive of the event will be available on the Company’s website at www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer.
ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.